Cogent Biosciences
COGT
53 hedge funds and large institutions have $62.5M invested in Cogent Biosciences in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 4 closing their positions.
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
13% more funds holding
Funds holding: 47 → 53 (+6)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.08% less ownership
Funds ownership: 11.9% → 11.83% (-0.08%)
1% less capital invested
Capital invested by funds: $62.8M → $62.5M (-$345K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.44M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.1M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$427K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$318K |
| 5 |
Millennium Management
New York
|
+$308K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.33M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.03M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$408K |
| 4 |
Walleye Trading
New York
|
-$288K |
| 5 |
D.E. Shaw & Co
New York
|
-$242K |
COGT Hedge Fund Activity: Q1 2019 in Review
53 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2019, worth a combined $62.5M — down 0.55% from $62.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new COGT positions and 4 closed out — a net gain of 6 holders — while 16 added to existing stakes and 13 trimmed.
The largest buyer was Sectoral Asset Management, adding an estimated $1.44M. The largest seller was Fidelity Investments, cutting an estimated $2.33M.
- 53 institutional investors held Cogent Biosciences (COGT) as of Q1 2019, up from 47 in Q4 2018.
- Funds reported $62.5M of Cogent Biosciences stock for Q1 2019, down 0.55% quarter-over-quarter.
- 10 funds opened new Cogent Biosciences positions in Q1 2019 and 4 closed out, a net change of +6 holders.
- The largest Cogent Biosciences buyer in Q1 2019 was Sectoral Asset Management, an estimated $1.44M added.
- The largest Cogent Biosciences seller in Q1 2019 was Fidelity Investments, an estimated $2.33M sold.
Based on aggregated 13F filings for Q1 2019.